Key Rare Disease Treatment Market Players:
- Roche Holding AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Johnson & Johnson
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Co.
- Amgen Inc.
- Biogen Inc.
- Alexion
- Vertex Pharmaceuticals
- Regeneron Pharmaceuticals
- CSL Behring
- Sarepta Therapeutics
- UCB S.A.
- Ipsen
- Chugai Pharmaceutical
- Kyowa Kirin
- Dr. Reddy’s Laboratories
- Samsung Biologics
The global rare disease treatment market is highly consolidated, with several biopharmaceutical giants like Pfizer, Roche, Takeda, and Sanofi controlling a notable share of the market. These companies are highly focused on strengthening their portfolios in this category through the acquisition of orphan drug designations, innovation in gene and cell therapy, and strategic expansion in regional territories to maintain their dominance over the net revenue generation in this sector. On the other hand, several key players from Asia Pacific are debuting via biosimilar pathways and public-private partnerships.
Here is a list of key players operating in the market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In 2024, the industry size of rare disease treatment was USD 5.8 billion.
The global rare disease treatment market size was USD 232.2 billion in 2024 and is estimated to reach USD 792.8 billion by the end of 2037, expanding at a CAGR of 10.35% during the forecast period, i.e., 2025-2037. By the end of 2025, the industry size of rare disease treatment is expected to reach USD 243.1 billion.
Roche Holding AG, Pfizer Inc, Sanofi S.A., Novartis AG, Takeda Pharmaceutical Co.Amgen Inc., Biogen Inc., Alexion, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, CSL Behring, Sarepta Therapeutics, UCB S.A., Ipsen, Chugai Pharmaceutical, Kyowa Kirin, Dr. Reddy’s Laboratories, Samsung Biologics are some of the leading companies in the market.
The biologics segment is projected to lead the rare disease treatment market during the forecast period.
North America is projected to dominate the rare disease treatment market during the forecast period.
